Navigation Links
Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
Date:5/7/2008

Company Increases Revenue Guidance for 2008

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the first quarter of fiscal 2008.

For the quarter ended March 31, 2008, Volcano reported revenues of $36.6 million, a 24 percent increase over revenues of $29.6 million in the same period a year ago. The company said IVUS disposable revenues increased 30 percent versus the first quarter of 2007, reflecting the growth of its installed base and broader IVUS adoption.

For the first quarter of 2008, the company reported a net loss on a GAAP basis of $2.3 million, or $0.05 per share. Included in this loss is $2.9 million in due diligence, legal and accounting expenses related to an acquisition that was not consummated. In the first quarter of 2007, the company reported GAAP net income of $1.7 million, or $0.04 per diluted share.

Excluding the aforementioned due diligence costs, stock-based compensation expense and in-process research and development expenses totaling $5.1 million, Volcano had non-GAAP net income of $2.8 million, or $0.06 per diluted share. In the first quarter of 2007, excluding stock-based compensation expense of $1.2 million, Volcano had net income of $2.9 million, or $0.07 per diluted share. Weighted average diluted shares at the end of the quarter were 47.0 million versus 41.7 million a year ago, reflecting the impact of the company's equity offering that was completed in the fourth quarter of 2007. A reconciliation of the company's GAAP and non-GAAP results can be found in today's earnings news release on the company's website at http://www.volcanocorp.com.

/p>

Interest expense (4) - - - (4)

Exchange rate gain 1,679 - - - 1,679

Income (loss)

before provision

for income taxes (2,118) 2,061 175 2,878 2,996

Provision for

income taxes 208 - - - 208

Net income (loss) $(2,326) $2,061 $175 $2,878 $2,788

Net income (loss)

per share - basic $(0.05) $0.04 $0.00 $0.06 $0.06

Net income (loss)

per share -

diluted $(0.05) $0.04 $0.00 $0.06 $0.06

Weighted-average

shares outstanding

- basic 47,030 47,030

Weighted-average

shares outstanding

- diluted 47,030 49,698

Three Months Ended March 31, 2007

In-process Acquisition

Stock-based research due

GAAP compensation and diligence Non-GAAP

results expense development costs results

Revenues $29,579 $- $- $- $29,579

Cost of revenues 10,865 (112) - - 10,753

Gross profit 18,714 112 - - 18,826

Operating expenses:

Selling, general

and

administrative 12,584 (923) - - 11,661

Research and

development 4,688 (208) - - 4,480

Amortization of

intangibles 786 - - - 786

Total operating

expenses 18,058 (1,131) - - 16,927

Operating income 656 1,243 - - 1,899

Interest income 1,195 - - - 1,195

Interest expense (89) - - - (89)

Exchange rate gain 122 - - - 122

Income before

provision for

income taxes 1,884 1,243 - - 3,127

Provision for

income taxes 210 - - - 210

Net income $1,674 $1,243 $- $- $2,917

Net income per

share - basic $0.04 $0.03 $- $- $0.08

Net income per

share - diluted $0.04 $0.03 $- $- $0.07

Weighted-average

shares outstanding -

basic 37,964 37,964

Weighted-average

shares outstanding -

diluted 41,685 41,685

Use of Non-GAAP Financial Measures

This press release includes certain non-GAAP financial information as defined by the U.S. Securities and Exchange Commission Regulation G. Pursuant to the requirements of this regulation, a reconciliation of this non-GAAP financial information to our financial statements as prepared under generally accepted accounting principles in the United States (GAAP) is included in this press release. Non-GAAP financial measures provide an indication of our performance before certain charges. Our management believes that in order to properly understand our short-term and long-term financial trends, investors may wish to consider the impact of these charges. These charges result from facts and circumstances that vary in frequency and/or impact on continuing operations. Our management believes that these items should be excluded when comparing our current operating results with those of prior periods as stock- based compensation is a non-cash expense, in-process research and development relates to the costs associated with the December 2007 acquisition of CardioSpectra, Inc., and the acquisition due diligence costs incurred in the first quarter of 2008 are not reflective of our core operating activities. In addition, our management uses results of operations before certain charges to evaluate the operational performance of the company and as a basis for strategic planning. Investors should note that the non-GAAP financial measures used by the company may not be the same non-GAAP financial measures, and may not be calculated in the same manner, as those of other companies. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP.

VOLCANO CORPORATION

REVENUE SUMMARY

(in millions)

(Unaudited)

Q1 '08 Q1 '07 Growth %

IVUS Systems:

United States $3.8 $3.7 1%

Japan 0.9 0.7 32%

Europe 1.2 0.8 47%

Rest of World 0.5 0.6 -15%

Total IVUS Systems $6.4 $5.8 9%

IVUS Disposables:

United States $11.6 $9.4 23%

Japan 8.8 6.1 43%

Europe 4.0 3.2 27%

Rest of World 0.8 0.6 31%

Total IVUS Disposables $25.2 $19.3 30%

FM:

United States $1.9 $1.6 19%

Japan 0.2 0.7 -69%

Europe 1.5 1.2 26%

Rest of World 0.1 0.2 -14%

Total FM $3.7 $3.7 2%

Other 1.3 0.8 71%

Total $36.6 $29.6 24%

"Volcano began 2008 with strong momentum by generating excellent revenue growth with our IVUS offerings and in our major geographies. Our IVUS disposable revenues were particularly strong, with year-over-year increases of 43 percent in Japan, 23 percent in the U.S. and 27 percent in Europe," said Scott Huennekens, president and chief executive officer.

"In addition, we have a solid pipeline of orders from customers awaiting the availability of IVUS systems with new features that we began shipping in the second quarter. Market adoption of IVUS continues to grow, driven by the growing volume of data demonstrating its value, our innovative and industry-leading technology that makes IVUS faster, easier and simpler to use and our effective sales, marketing and distribution programs. In addition, we are benefitting from an increasingly favorable environment for percutaneous coronary intervention (PCI) and stenting procedures," he continued.

"During the first quarter, we enhanced our technology advantage with the formal launch in the U.S. and Europe of our Revolution rotational catheter and FFR (fractional flow reserve) on the s5 family of IVUS consoles at the American College of Cardiology meeting. Full market release shipments are expected to begin in the current quarter. We are now the only IVUS company offering both phased array and rotational catheters in a single integrated console. In Japan, we received regulatory approval for the s5 tower last week and are on schedule for the full market release of the Revolution on the s5 family in the third quarter. In addition, we announced a new collaboration with Royal Philips Electronics under which they will resell Volcano-branded s5i IVUS systems and accessories alongside the Philips Allura Xper FD X-ray systems. We will continue to leverage this partnership, as well as those we have established with other leading cath lab equipment and stent companies, in our efforts to increase the rate of integrated lab adoption and win market share."

Volcano also said its product development programs remain on track, including the expected commercial launch in the second half of 2009 of its first image-guided therapy offering, a balloon and IVUS on the same catheter. Volcano also expects U.S. and European regulatory approval in the second half of 2009 for its initial Optical Coherence Tomography product incorporating the technology that the company acquired with its purchase of CardioSpectra at the end of 2007.

"Our new product initiatives are designed to offer a variety of modalities built around our s5i offering and to position Volcano to address a number of very sizeable therapy markets with innovative platform technologies," Huennekens noted. "We will also continue to explore strategic opportunities that provide offerings for our existing customer base and meet our growth rate, gross margin and valuation objectives," he added.

Guidance for 2008

The company updated its prior guidance for 2008. Volcano said it now expects revenues for the year will be in the range of approximately $164-$168 million. This compares with prior guidance of $158-$162 million, and represents an increase of approximately 26-29 percent over revenues in 2007. Gross margin is expected to be in the range of 60-61 percent, with the company expecting to exit 2008 with margins in the range of 63-64 percent. Operating expenses, including stock-based compensation, the $2.9 million in due diligence expense recorded in the first quarter, and approximately $3.1 million of intangible amortization, are expected to be 65-66 percent of revenues.

On a GAAP basis, the company expects to report a net loss of approximately $0.06-$0.10 per share. This compares to prior guidance for a net loss of $0.02-$0.04 per share. The decrease in guidance for earnings per share, despite the expected increase in revenues, reflects the due diligence expense, reduced interest income due to declining interest rates, increased sales and marketing expenses related to the revenue increase and increased research and development spending on programs to accelerate the commercialization of new products. The company expects to begin being profitable on a GAAP basis in the fourth quarter. Excluding stock-based compensation expense of approximately $10.0 million, due diligence costs and in-process research and development, Volcano expects to report non-GAAP net income of $0.16-$0.20 per diluted share. This compares with prior guidance for net income on this basis of $0.16-$0.18 per diluted share. Weighted average shares outstanding in 2008 are expected to be approximately 47.7 million basic shares and 50.4 million shares on a diluted basis.

Conference Call

The company will hold a conference call at 2 p.m., Pacific Daylight Time, (5 p.m., Eastern Daylight Time) today. The teleconference can be accessed by calling (719) 325-4897, passcode 9694232, or via the company's website at http://www.volcanocorp.com. Please dial in or access the website 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available until May 16 at (719) 457-0820, passcode 9694232, and via the company's website.

Volcano Corporation

Volcano Corporation (Nasdaq: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options, such as VH(TM) tissue characterization and ChromaFlo(R). Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra-high resolution Optical Coherence Tomography (OCT) systems and catheters. Currently, more than 3,300 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States. For more information, visit the company's website at http://www.volcanocorp.com.

Use of Non-GAAP Financial Measures

This press release includes certain non-GAAP financial information as defined by the U.S. Securities and Exchange Commission Regulation G. Pursuant to the requirements of this regulation, a reconciliation of this non-GAAP financial information to our financial statements as prepared under generally accepted accounting principles in the United States (GAAP) is included in this press release. Non-GAAP financial measures provide an indication of our performance before certain charges. Our management believes that in order to properly understand our short-term and long-term financial trends, investors may wish to consider the impact of these charges. These charges result from facts and circumstances that vary in frequency and/or impact on continuing operations. Our management believes that these items should be excluded when comparing our current operating results with those of prior periods as stock-based compensation is a non-cash expense, in-process research and development relates to the costs associated with the December 2007 acquisition of CardioSpectra, Inc. and the acquisition due diligence costs incurred in the first quarter of 2008 are not reflective of our core operating activities. In addition, our management uses results of operations before certain charges to evaluate the operational performance of the company and as a basis for strategic planning. Investors should note that the non-GAAP financial measures used by the company may not be the same non-GAAP financial measures, and may not be calculated in the same manner, as those of other companies. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding the company's financial guidance for 2008, regulatory approvals and the impact of obtaining regulatory approvals, market adoption of the company's technology, the impact of clinical and other technical data, the safety and efficacy of the company's products, the success and timing of product development and clinical trial programs, growth strategies and market development, product sales and use and merger and acquisition activities. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

VOLCANO CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(Unaudited)

March 31, December 31,

2008 2007

Assets

Current assets:

Cash and cash equivalents $132,572 $122,913

Short-term available-for-sale

investments 55,539 66,205

Accounts receivable, net 25,293 27,976

Inventories 22,399 21,243

Prepaid expenses and other current

assets 3,979 3,997

Total current assets 239,782 242,334

Restricted cash 376 365

Property and equipment, net 14,814 13,692

Intangible assets, net 8,641 9,385

Other non-current assets 804 798

$264,417 $266,574

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable $10,051 $11,077

Accrued compensation 8,250 9,083

Accrued expenses and other current

liabilities 6,326 6,600

Deferred revenues 5,796 5,360

Current maturities of long-term debt 58 120

Total current liabilities 30,481 32,240

Long-term debt 78 78

Deferred license fee 1,063 1,125

Other 181 194

Total liabilities 31,803 33,637

Stockholders' equity 232,614 232,937

$264,417 $266,574

VOLCANO CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(Unaudited)

Three Months Ended March 31,

2008 2007

Revenues $36,647 $29,579

Cost of revenues 13,629 10,865

Gross profit 23,018 18,714

Operating expenses:

Selling, general and administrative 22,059 12,584

Research and development 5,637 4,688

In-process research and development 175 -

Amortization of intangibles 773 786

Total operating expenses 28,644 18,058

Operating income (loss) (5,626) 656

Interest income 1,833 1,195

Interest expense (4) (89)

Exchange rate gain 1,679 122

Income (loss) before provision for income

taxes (2,118) 1,884

Provision for income taxes 208 210

Net income (loss) $(2,326) $1,674

Net income (loss) per share - basic $(0.05) $0.04

Net income (loss) per share - diluted $(0.05) $0.04

Weighted-average shares outstanding - basic 47,030 37,964

Weighted-average shares outstanding - diluted 47,030 41,685

VOLCANO CORPORATION

RECONCILIATION OF GAAP AND NON-GAAP OPERATING RESULTS

(in thousands, except per share data)

(Unaudited)

Three Months Ended March 31, 2008

In-process Acquisition

Stock-based research due

GAAP compensation and diligence Non-GAAP

results expense development costs results

Revenues $36,647 $- $- $- $36,647

Cost of revenues 13,629 (191) - - 13,438

Gross profit 23,018 191 - - 23,209

Operating expenses:

Selling, general

and

administrative 22,059 (1,501) - (2,878) 17,680

Research and

development 5,637 (369) - - 5,268

In-process

research and

development 175 - (175) - -

Amortization of

intangibles 773 - - - 773

Total operating

expenses 28,644 (1,870) (175) (2,878) 23,721

Operating loss (5,626) 2,061 175 2,878 (512)

Interest income 1,833 - - - 1,833<
'/>"/>

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
2. Volcano Corporation Announces Pricing of Common Stock Offering
3. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
4. Volcano Announces Closing of CardioSpectra Acquisition
5. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
6. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
7. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
8. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... India , April 28, 2016 ... JT, Stirling, and Brayton Cryocoolers), Service (Technical Support, Product ... and Geography - Global Forecast to 2022", published by ... USD 2.94 Billion by 2022, at a CAGR of ... 70 market data Tables and 94 Figures spread through ...
(Date:4/28/2016)... Windsor, Connecticut (PRWEB) , ... April 28, 2016 ... ... Morris Group, Inc., will hold an open house for regional manufacturers at its ... and displays from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 ...
(Date:4/27/2016)... British Columbia , April 27, 2016 /PRNewswire/ ... oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... im Anschluss an ihre Pressemitteilung vom 13. August ... erhalten hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten ... 4.000.000 Kanadische Dollar zu bringen. Davon wurden 157.900.000 ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing ... disease and testing novel treatments in small animal subjects. Simultaneous PET/MRI imaging offers ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):